CRU 2025: Exploring minimally invasive glaucoma surgeries
FDA issues Complete Response Letter to Aldeyra Therapeutics for resubmitted New Drug Application of reproxalap
Advancing presbyopia treatment through optimized design
Emerging opportunities in inherited retinal diseases